

Nancie M Archin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6194181/publications.pdf>

Version: 2024-02-01

47
papers

4,559
citations

136885

32
h-index

214721

47
g-index

49
all docs

49
docs citations

49
times ranked

4055
citing authors

#	ARTICLE	IF	CITATIONS
1	Stable Latent HIV Infection and Low-level Viremia Despite Treatment With the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. <i>Journal of Infectious Diseases</i> , 2022, 225, 856-861.	1.9	22
2	Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52. <i>IScience</i> , 2022, 25, 103649.	1.9	6
3	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1389-1396.	2.9	9
4	Combined noncanonical NF- κ B agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	17
5	Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA. <i>Journal of Virology</i> , 2021, 95, .	1.5	47
6	HIV and women in the USA: what we know and where to go from here. <i>Lancet, The</i> , 2021, 397, 1107-1115.	6.3	35
7	Defining Stable Reference Genes in HIV Latency Reversal Experiments. <i>Journal of Virology</i> , 2021, 95, .	1.5	5
8	Reliable Estimation of CD8 T Cell Inhibition of In Vitro HIV-1 Replication. <i>Frontiers in Immunology</i> , 2021, 12, 666991.	2.2	1
9	Immunological Correlates of the HIV-1 Replication-Competent Reservoir Size. <i>Clinical Infectious Diseases</i> , 2021, 73, 1528-1531.	2.9	4
10	Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2021, 224, 92-100.	1.9	57
11	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. <i>Nature Medicine</i> , 2021, 27, 2085-2098.	15.2	146
12	Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal. <i>ACS Infectious Diseases</i> , 2020, 6, 1719-1733.	1.8	17
13	Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 1843-1852.	1.9	22
14	Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection. <i>Scientific Reports</i> , 2020, 10, 5134.	1.6	32
15	Curing HIV: Seeking to Target and Clear Persistent Infection. <i>Cell</i> , 2020, 181, 189-206.	13.5	126
16	Systemic HIV and SIV latency reversal via non-canonical NF- κ B signalling in vivo. <i>Nature</i> , 2020, 578, 160-165.	13.7	210
17	Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
18	The HIV-1 latent reservoir is largely sensitive to circulating T cells. <i>ELife</i> , 2020, 9, .	2.8	25

#	ARTICLE	IF	CITATIONS
19	Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir. <i>ELife</i> , 2020, 9, .	2.8	63
20	The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	141
21	New Frontiers in Measuring and Characterizing the HIV Reservoir. <i>Frontiers in Microbiology</i> , 2019, 10, 2878.	1.5	43
22	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. <i>Clinical Infectious Diseases</i> , 2019, 69, 1345-1352.	2.9	58
23	HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. <i>Molecular Therapy</i> , 2018, 26, 2496-2506.	3.7	32
24	HIV latency is reversed by ACSS2-driven histone crotonylation. <i>Journal of Clinical Investigation</i> , 2018, 128, 1190-1198.	3.9	109
25	Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation. <i>Cell Reports</i> , 2017, 18, 1324-1334.	2.9	69
26	SLDAssay: A software package and web tool for analyzing limiting dilution assays. <i>Journal of Immunological Methods</i> , 2017, 450, 10-16.	0.6	27
27	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. <i>JCI Insight</i> , 2017, 2, .	2.3	59
28	Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. <i>Journal of Clinical Investigation</i> , 2017, 127, 3126-3135.	3.9	165
29	In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. <i>Retrovirology</i> , 2016, 13, 36.	0.9	54
30	Peripheral CD4 ⁺ T Cells Are a Novel Reservoir of Latent HIV Infection. <i>PLoS Pathogens</i> , 2015, 11, e1005201.	2.1	66
31	Dual-Affinity Re-Targeting proteins direct T cell-mediated cytotoxicity of latently HIV-infected cells. <i>Journal of Clinical Investigation</i> , 2015, 125, 4077-4090.	3.9	124
32	H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4 ⁺ T Cells. <i>Journal of Virology</i> , 2015, 89, 8392-8405.	1.5	60
33	Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. <i>Journal of Infectious Diseases</i> , 2015, 212, 1361-1365.	1.9	362
34	<i>Staphylococcus aureus</i> Infection in Humanized Mice: A New Model to Study Pathogenicity Associated With Human Immune Response. <i>Journal of Infectious Diseases</i> , 2015, 212, 435-444.	1.9	36
35	Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. <i>Journal of Infectious Diseases</i> , 2015, 212, 258-263.	1.9	86
36	Broadly-specific Cytotoxic T Cells Targeting Multiple HIV Antigens Are Expanded From HIV+ Patients: Implications for Immunotherapy. <i>Molecular Therapy</i> , 2015, 23, 387-395.	3.7	46

#	ARTICLE	IF	CITATIONS
37	Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART. PLoS Pathogens, 2014, 10, e1003872.	2.1	101
38	Emerging strategies to deplete the HIV reservoir. Current Opinion in Infectious Diseases, 2014, 27, 29-35.	1.3	164
39	Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nature Reviews Microbiology, 2014, 12, 750-764.	13.6	247
40	Quantitation of Replication-Competent HIV-1 in Populations of Resting CD4 ⁺ T Cells. Journal of Virology, 2014, 88, 14070-14077.	1.5	146
41	Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection. PLoS ONE, 2014, 9, e102684.	1.1	65
42	An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4 ⁺ T Cells from Aviremic Patients. PLoS Pathogens, 2013, 9, e1003834.	2.1	360
43	Immediate antiviral therapy appears to restrict resting CD4 ⁺ cell HIV-1 infection without accelerating the decay of latent infection. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9523-9528.	3.3	202
44	A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression. Journal of Virology, 2009, 83, 4749-4756.	1.5	183
45	Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. Aids, 2009, 23, 1799-1806.	1.0	154
46	Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid. AIDS Research and Human Retroviruses, 2009, 25, 207-212.	0.5	317
47	Coaxing HIV-1 from resting CD4 T cells. Aids, 2004, 18, 1101-1108.	1.0	233